{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:34:35Z","timestamp":1790789675470,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Joint project of Luzhou City and Southwest Medical University","award":["2018LZXNYD-ZK22"],"award-info":[{"award-number":["2018LZXNYD-ZK22"]}]},{"name":"Application foundation project of Luzhou science and technology and talent Bureau","award":["2021-JYJ-65"],"award-info":[{"award-number":["2021-JYJ-65"]}]},{"name":"University level funding program of Southwest Medical University","award":["2019ZQN055"],"award-info":[{"award-number":["2019ZQN055"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03663-6","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T13:33:59Z","timestamp":1724420039000},"page":"988-999","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Overexpression of cytoplasmic poly(A)-binding protein 1 as a biomarker for the prognosis and selection of postoperative regimen in breast cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Yunqiu","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-685X","authenticated-orcid":false,"given":"Wenbo","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"issue":"12","key":"3663_CR1","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.3390\/ijms23126806","volume":"23","author":"M Park","year":"2022","unstructured":"Park M, Kim D, Ko S, Kim A, Mo K, Yoon H. Breast cancer metastasis: mechanisms and therapeutic implications. Int J Mol Sci. 2022;23(12):6806.","journal-title":"Int J Mol Sci"},{"key":"3663_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","volume":"60","author":"Y Liang","year":"2020","unstructured":"Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14\u201327.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"3663_CR3","doi-asserted-by":"publisher","first-page":"C343","DOI":"10.1152\/ajpcell.00109.2021","volume":"321","author":"KM Turner","year":"2021","unstructured":"Turner KM, Yeo SK, Holm TM, Shaughnessy E, Guan JL. Heterogeneity within molecular subtypes of breast cancer. Am J Physiol Cell Physiol. 2021;321(2):C343\u201354.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"8","key":"3663_CR4","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th\u00fcrlimann B, Senn HJ, et al. Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736\u201347.","journal-title":"Ann Oncol"},{"key":"3663_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2147\/DDDT.S336643","volume":"16","author":"Z Li","year":"2022","unstructured":"Li Z, Wei H, Li S, Wu P, Mao X. The role of progesterone receptors in breast cancer. Drug Des Devel Ther. 2022;16:305\u201314.","journal-title":"Drug Des Devel Ther"},{"issue":"25","key":"3663_CR6","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1200\/JCO.2013.54.1870","volume":"32","author":"F Ades","year":"2014","unstructured":"Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014;32(25):2794\u2013803.","journal-title":"J Clin Oncol"},{"key":"3663_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12885-015-1121-4","volume":"15","author":"SY Bae","year":"2015","unstructured":"Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, et al. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer. 2015;15:138.","journal-title":"BMC Cancer"},{"issue":"12","key":"3663_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12032-022-01849-y","volume":"39","author":"R Gupta","year":"2022","unstructured":"Gupta R, Gupta S, Antonios B, Ghimire B, Jindal V, Deol J, et al. Therapeutic landscape of advanced HER2-positive breast cancer in 2022. Med Oncol. 2022;39(12):258.","journal-title":"Med Oncol"},{"issue":"2","key":"3663_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","volume":"177","author":"G Jerusalem","year":"2019","unstructured":"Jerusalem G, Lancellotti P, Kim SB. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat. 2019;177(2):237\u201350.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"3663_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101\u201326.","journal-title":"Nat Rev Drug Discov"},{"key":"3663_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103883","volume":"181","author":"Y Wu","year":"2022","unstructured":"Wu Y, Zhong R, Ma F. HER2-low breast cancer: novel detections and treatment advances. Crit Rev Oncol Hematol. 2022;181: 103883.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"3663_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"key":"3663_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ejca.2022.08.022","volume":"75","author":"X Baez-Navarro","year":"2022","unstructured":"Baez-Navarro X, Salgado R, Denkert C, Lennerz JK, Penault-Llorca F, Viale G, et al. Selecting patients with HER2-low breast cancer: getting out of the tangle. Eur J Cancer. 2022;75:187\u201392.","journal-title":"Eur J Cancer"},{"issue":"5","key":"3663_CR14","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1016\/j.clbc.2018.07.023","volume":"18","author":"Z Sporikova","year":"2018","unstructured":"Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic markers in triple-negative breast cancer. Clin Breast Cancer. 2018;18(5):e841\u201350.","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"3663_CR15","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1158\/2159-8290.CD-22-0200","volume":"12","author":"M Anurag","year":"2022","unstructured":"Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, et al. Proteogenomic markers of chemotherapy resistance and response in triple-negative breast cancer. Cancer Discov. 2022;12(11):2586\u2013605.","journal-title":"Cancer Discov"},{"issue":"11","key":"3663_CR16","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/s41417-022-00473-2","volume":"29","author":"J Ma","year":"2022","unstructured":"Ma J, Chen C, Liu S, Ji J, Wu D, Huang P, et al. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis. Cancer Gene Ther. 2022;29(11):1578\u201389.","journal-title":"Cancer Gene Ther"},{"issue":"19","key":"3663_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1631\/jzus.B1900709","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu J, Wu KJ, Jia QJ, Ding XF. Roles of miRNA and lncRNA in triple-negative breast cancer. J Zhejiang Univ Sci B. 2020;21(19):673\u201389.","journal-title":"J Zhejiang Univ Sci B"},{"key":"3663_CR18","doi-asserted-by":"publisher","first-page":"1025291","DOI":"10.3389\/fonc.2022.1025291","volume":"12","author":"Y Qi","year":"2022","unstructured":"Qi Y, Wang M, Jiang Q. PABPC1\u2013mRNA stability, protein translation and tumorigenesis. Front Oncol. 2022;12:1025291.","journal-title":"Front Oncol"},{"issue":"6","key":"3663_CR19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1042\/BST20150171","volume":"43","author":"NK Gray","year":"2015","unstructured":"Gray NK, Hrab\u00e1lkov\u00e1 L, Scanlon JP, Smith RW. Poly(A)-binding proteins and mRNA localization: who rules the roost? Biochem Soc Trans. 2015;43(6):1277\u201384.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"3663_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12885-023-10629-4","volume":"23","author":"F Ling","year":"2023","unstructured":"Ling F, Xu S, Li X, Sun X, Long W. Cytoplasmic poly(A)-binding protein 1 (PABPC1) is a prognostic biomarker to predict survival in nasopharyngeal carcinoma regardless of chemoradiotherapy. BMC Cancer. 2023;23(1):169.","journal-title":"BMC Cancer"},{"issue":"10","key":"3663_CR21","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.1007\/s11033-021-06681-7","volume":"48","author":"M Shakeel","year":"2021","unstructured":"Shakeel M, Khan SA, Mughal AJ, Irfan M, Hoessli DC, Choudhary MI, et al. Distinct genetic landscape and a low response to doxorubicin in a luminal-A breast cancer cell line of Pakistani origin. Mol Biol Rep. 2021;48(10):6821\u20139.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"3663_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/PAP.0000000000000232","volume":"27","author":"JYS Tsang","year":"2020","unstructured":"Tsang JYS, Tse GM. Molecular classification of breast cancer. Adv Anat Pathol. 2020;27(1):27\u201335.","journal-title":"Adv Anat Pathol"},{"issue":"2","key":"3663_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.21147\/j.issn.1000-9604.2019.02.02","volume":"31","author":"National Health Commission of the People's Republic of China","year":"2019","unstructured":"National Health Commission of the People\u2019s Republic of China. Chinese guidelines for diagnosis and treatment of breast cancer 2018 (English version). Chin J Cancer Res. 2019;31(2):259\u201377.","journal-title":"Chin J Cancer Res"},{"issue":"5","key":"3663_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020;144(5):545\u201363.","journal-title":"Arch Pathol Lab Med"},{"issue":"20","key":"3663_CR25","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105\u201322.","journal-title":"J Clin Oncol"},{"key":"3663_CR26","doi-asserted-by":"publisher","first-page":"7054134","DOI":"10.1155\/2021\/7054134","volume":"2021","author":"C Ameh-Mensah","year":"2021","unstructured":"Ameh-Mensah C, Duduyemi BM, Bedu-Addo K, Atta Manu E, Opoku F, Titiloye N. The analysis of bcl-2 in association with p53 and ki-67 in triple negative breast cancer and other molecular subtypes in Ghana. J Oncol. 2021;2021:7054134.","journal-title":"J Oncol"},{"issue":"21","key":"3663_CR27","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.3390\/cancers14215444","volume":"14","author":"R Be\u0148a\u010dka","year":"2022","unstructured":"Be\u0148a\u010dka R, Szab\u00f3ov\u00e1 D, Gu\u013ea\u0161ov\u00e1 Z, Hertelyov\u00e1 Z, Rado\u0148\u00e1k J. Classic and new markers in diagnostics and classification of breast cancer. Cancers (Basel). 2022;14(21):5444.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"3663_CR28","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00109-021-02136-5","volume":"99","author":"O Saatci","year":"2021","unstructured":"Saatci O, Huynh-Dam KT, Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med (Berl). 2021;99(12):1691\u2013710.","journal-title":"J Mol Med (Berl)"},{"issue":"3","key":"3663_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s12282-023-01437-6","volume":"30","author":"C Song","year":"2023","unstructured":"Song C, Kendi AT, Shim JY, Jung D, Kang PS, Lowe VJ, et al. ER-\/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor. Breast Cancer. 2023;30(3):436\u201352.","journal-title":"Breast Cancer"},{"issue":"1","key":"3663_CR30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/ijc.33539","volume":"149","author":"F Beltjens","year":"2021","unstructured":"Beltjens F, Molly D, Bertaut A, Richard C, Desmoulins I, Loustalot C, et al. ER-\/PR+ breast cancer: a distinct entity, which is morphologically and molecularly close to triple-negative breast cancer. Int J Cancer. 2021;149(1):200\u201313.","journal-title":"Int J Cancer"},{"issue":"8","key":"3663_CR31","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3390\/jpm11080808","volume":"11","author":"A Burguin","year":"2021","unstructured":"Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Pers Med. 2021;11(8):808.","journal-title":"J Pers Med"},{"issue":"1","key":"3663_CR32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12957-020-02089-y","volume":"18","author":"Y Li","year":"2020","unstructured":"Li Y, Ma L. Efficacy of chemotherapy for lymph node-positive luminal A subtype breast cancer patients: an updated meta-analysis. World J Surg Oncol. 2020;18(1):316.","journal-title":"World J Surg Oncol"},{"issue":"39","key":"3663_CR33","doi-asserted-by":"publisher","first-page":"63571","DOI":"10.18632\/oncotarget.11541","volume":"7","author":"QQ Xu","year":"2016","unstructured":"Xu QQ, Pan B, Wang CJ, Zhou YD, Mao F, Lin Y, et al. HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis. Oncotarget. 2016;7(39):63571\u201382.","journal-title":"Oncotarget"},{"issue":"17","key":"3663_CR34","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.3390\/cancers14174250","volume":"14","author":"L Shu","year":"2022","unstructured":"Shu L, Tong Y, Li Z, Chen X, Shen K. Can HER2 1+ breast cancer be considered as HER2-low tumor? A comparison of clinicopathological features, quantitative HER2 mRNA levels, and prognosis among HER2-negative breast cancer. Cancers (Basel). 2022;14(17):4250.","journal-title":"Cancers (Basel)"},{"key":"3663_CR35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annu Rev Pathol. 2022;17:181\u2013204.","journal-title":"Annu Rev Pathol"},{"issue":"7","key":"3663_CR36","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.3390\/curroncol29070378","volume":"29","author":"I MacDonald","year":"2022","unstructured":"MacDonald I, Nixon NA, Khan OF. Triple-negative breast cancer: a review of current curative intent therapies. Curr Oncol. 2022;29(7):4768\u201378.","journal-title":"Curr Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03663-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03663-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03663-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:42:38Z","timestamp":1742190158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03663-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["3663"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03663-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study procedure was approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University (KY2019126). All the procedures performed in this study using human data followed the Declaration of Helsinki. Informed consent was waived by the Ethics Committee of the Affiliated Hospital of Southwest Medical University due to the retrospective nature of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study is exempt from informed consent as it is a retrospective data collection from the patient's medical records. The data included are part of the usual clinical history of these patients, and data are coded, so they do not suppose any risk to the integrity of the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}